Immune exhaustion of T cells induced by chronic antigen stimulation and a bottleneck in cell therapy commercialization T cells residing within the microenvironment of chronic infectious diseases and malignant solid tumors are continuously exposed to antigenic noise, leading to paralysis of their intrinsic cytotoxic effector functions and overexpression of immune checkpoint receptors such as PD‑1 and TIM‑3, thereby entering a state of T‑cell exhaustion. Conventional adoptive cell therapy (ACT) guidelines rely on harvesting already exhausted peripheral blood T cells from the patient, expanding them ex vivo, and reinfusing them, which creates a blind spot wherein immediate post‑infusion cell death and functional incapacitation occur. The extreme variability and high cost associated with patient‑specific autologous manufacturing constitute a persistent technical bottleneck that stalls the global lead time for commercializing anticancer immune cell therapies.

Establishment of a T‑iPSC dedifferentiation platform: Xeno‑free culture and genome‑editing‑driven proactive immune‑rejection control To neutralize the functional limitations of autologous cells and enable large‑scale supply of uniformly high‑quality cell therapies, we fully activated a T‑iPSC differentiation platform that generates ‘rejuvenated’ T cells with reset immune proliferative activity from induced pluripotent stem cells (iPSCs). The team developed a xeno‑free manufacturing protocol that meets global clinical‑grade standards, thereby eliminating exogenous contamination risk at the source. Concurrently, we deployed CRISPR‑based gene editing to excise key histocompatibility loci such as HLA class I and II that trigger allo‑immune responses, achieving molecular tuning that suppresses intrinsic lymphocyte immunogenicity to below baseline levels.

Downstream signaling correction and synthetic receptor optimization to clamp GvHD risk To dramatically boost the tumor‑killing capacity of ex‑vivo differentiated regenerative T cells, we genetically re‑engineered intracellular signaling pathway modules to confer resistance to immune exhaustion. Furthermore, to mitigate the fatal adverse event of graft‑versus‑host disease (GvHD) inherent to off‑the‑shelf allogeneic cell therapies, we ablated the endogenous T‑cell receptor (TCR) and installed a cancer‑specific synthetic receptor architecture. This approach maximized effective target‑binding concentrations while demonstrably eliminating off‑target genotoxicity in preclinical models, thereby establishing robust preclinical integrity.

Standardization of the allogeneic off‑the‑shelf platform and establishment of next‑generation cell and gene therapy (CGT) standards The integrated immunology and regenerative stem‑cell engineering data repository redefines the T‑cell therapy paradigm from a narrowly limited autologous manufacturing model to a programmable allogeneic cell‑production infrastructure capable of large‑scale tank bioreactor culture under GMP specifications. By differentiating not only tumor‑targeting T cells but also immunosuppressive regulatory T cells (Tregs) from an iPSC backbone, we have completed a control‑panel interface for autoimmune disease and organ‑transplant rejection. The derived T‑iPSC differentiation kinetic constant will serve as a computational backbone for prospectively calculating CMC acceptance criteria in future global clinical programs, and will function as a master reference asset to exponentially shorten IND approval timelines for next‑generation off‑the‑shelf immune cell therapies.